Trial Condition(s):

Neoplasms

A Drug Utilization Study of Radium-223 in Sweden

Bayer Identifier:

17399

ClinicalTrials.gov Identifier:

NCT02331303

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The objective of this study is to evaluate the extent of potential off-label use of Xofigo in Sweden.

Inclusion Criteria
- Patients receiving Xofigo with data recorded at nuclear medicine centers in Sweden between 01 July 2014 and 30 June 2016 will be included in the study
Exclusion Criteria
- Patients receiving Xofigo in a clinical trial will not be included in this study

Trial Summary

Enrollment Goal
37
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Stockholm, Sweden

Status
Completed
 

Trial Design